We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
The current 0QSS market cap is 2.2B. The company's latest EPS is EUR -0.0074 and P/E is -572.97.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 4.45M | 5.28M | 3.72M | 4.18M | 6.65M |
| Operating Income | -43.62M | -64M | -68.83M | -56.52M | -27.15M |
| Net Income | -38.22M | -62.66M | -73.3M | -53.8M | -228k |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 167.84M | 118.55M | 80.4M | 66.77M | 45.81M |
| Total Liabilities | 22.24M | 32.99M | 53.86M | 43.92M | 22.32M |
| Total Equity | 145.6M | 85.56M | 26.54M | 22.85M | 23.49M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -39.27M | -43.31M | -51.72M | -56.77M | -31.76M |
| Investing | -15.04M | -19.84M | -1.48M | -345k | 38.13M |
| Financing | -818k | 39k | 25.45M | 44.71M | -1.77M |
| Market Cap | 2.2B |
| Price to Earnings Ratio | -572.97 |
| Price to Sales Ratio | 19.77 |
| Price to Cash Ratio | 3.39 |
| Price to Book Ratio | 5.59 |
| Dividend Yield | - |
| Shares Outstanding | 30.99M |
| Average Volume (1 week) | 9 |
| Average Volume (1 Month) | 10 |
| 52 Week Change | 0.0% |
| 52 Week High | 71.025 |
| 52 Week Low | 71.025 |
| Spread (Intraday) | 0.36 (4.88%) |
| Company Name | Phaxiam Therapeutics |
| Address |
60 avenue rockefeller lyon, rhone 69008 |
| Website | https://www.erytech.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
